Abstract WP348: Soluble C-type Lectin-Like Receptor 2 as a Biomarker in Patients with Acute Ischemic Stroke or TIA: A Multicenter, Prospective Cohort Study

Résumé fourni par la source

Background: We measured soluble C-type lectin-like receptor 2 (sCLEC-2), which is a new biomarker of platelet activation, to investigate clinical implications in patients with acute ischemic stroke (AIS) and TIA (Trial registration numbers: NCT05579405, UMIN 000048954). Methods: Plasma levels of sCLEC-2 were measured by high-sensitivity chemiluminescent enzyme immunoassay in 377 patients with AIS and 62 patients with TIA. Results: sCLEC-2/D-dimer ratio (mean±SD) at baseline (Day 1) was higher in patients with non-cardioembolic stroke/TIA (n=111, 491.9±433.7) than in those with cardioembolic stroke/TIA (n=52, 220.6±287.9) (t-test, p<0.0001) (patients on antithrombotics at baseline were excluded). Baseline sCLEC-2 levels (mean±SD) were 248.8±161.6, 277.6±210.6 (n=50), and 324.0±266.3 pg/ml in mild (NIHSS<6) (n=283), moderate (NIHSS 6-14) (n=50), and severe (NIHSS>14) (n=42) patients with AIS, respectively, which were higher in patients with severe AIS than in those with mild AIS (Tukey test, p=0.031). sCLEC-2 (mean±SD) at baseline was higher in patients with medium/large infarcts (n=97, 282.4±192.8 pg/ml) than in those with small infarcts (n=117, 233.6±115.1 pg/ml) among patients with non-cardioembolic plus non-lacunar stroke (t-test, p=0.012), while it was lower in medium/large infarcts (n=63, 231.9±184.0 pg/ml) than in those with small infarcts (n=26, 341.9±347.0 pg/ml) among patients with cardioembolic stroke (t-test, p=0.003). Mean sCLEC-2 was increased in patients with worsening (recurrence or deterioration) (n=17, +84.4 pg/ml) and decreased in those without worsening (n=271, -10.3 pg/ml) between Day 1 and Day 7 (Welch-corrected t test, p=0.013). Poor outcome (mRS>1) at discharge was more common in patients with increased sCLEC-2 than in those with decreased sCLEC-2 between Day 1 and Day 7 (61.4% vs 39.1%, Fisher’s exact test, p=0.002). Poor outcome at 3 months was more common in patients with high sCLEC-2 levels (156 pg/ml or more) than in those with normal sCLEC-2 levels (<156 pg/ml) at Day 7 (36.1% vs 13.0%, Fisher’s exact test, p=0.024). Conclusions: sCLEC-2 was a promising biomarker for subtyping of AIS/TIA, accessing stroke severity, elucidating pathophysiology, and predicting outcomes in patients with AIS or TIA.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.